Anagliptin

Anagliptin
Systematic (IUPAC) name

N-[2-[[2-[(2S)-2-Cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
Clinical data
Trade names	Suiny
Legal status	Approved in Japan
Routes of administration	Oral
Identifiers
CAS Number	739366-20-2
ATC code	None
ChemSpider	28492667
Chemical data
Formula	C₁₉H₂₅N₇O₂
Molar mass	383.45 g/mol
SMILES CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
InChI InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1 Key:LDXYBEHACFJIEL-HNNXBMFYSA-N

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.^[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".^[2]

References

↑ A.I. Graul, B. Lupone, E. Cruces and M. Stringer (2013). "2012 in Review - Part I: The Year's New Drugs and Biologics" (PDF). Drugs of Today 49 (1): 33–68. doi:10.1358/dot.2013.49.1.1933991.
↑ Kato, Noriyasu; Oka, Mitsuru; Murase, Takayo; Yoshida, Masahiro; Sakairi, Masao; Yamashita, Satoko; Yasuda, Yoshika; Yoshikawa, Aya; Hayashi, Yuuji; Makino, Mitsuhiro; Takeda, Motohiro; Mirensha, Yakufu; Kakigami, Takuji (2011). "Discovery and pharmacological characterization of N-\2-({2-\(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo\1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry 19 (23): 7221. doi:10.1016/j.bmc.2011.09.043.

Oral anti-diabetic drugs, insulins and insulin analogs, and other drugs used in diabetes (A10)

Insulin

Sensitizers

Biguanides	Metformin^# Buformin<sp>‡ Phenformin^‡

TZDs/"glitazones" (PPAR)	Ciglitazone^§ Darglitazone^§ Englitazone^§ Lobeglitazone Netoglitazone^§ Pioglitazone Rivoglitazone^† Rosiglitazone Troglitazone^‡

Dual PPAR agonists	Aleglitazar^† Muraglitazar^§ Saroglitazar Tesaglitazar^§

Secretagogues

K+ ATP

Sulfonylureas	1st generation: Acetohexamide Carbutamide Chlorpropamide Metahexamide Tolbutamide Tolazamide 2nd generation: Glibenclamide (Glyburide)^# Glibornuride Glicetanile Gliclazide Gliflumide Glipizide Gliquidone Glisoxepide Glyclopyramide Glimepiride

Meglitinides/"glinides"	Nateglinide Repaglinide Mitiglinide

GLP-1 agonists

DPP-4 inhibitors

GPR40 Free fatty acid receptor 1

Fasiglifam^†

Analogs/other insulins

fast-acting (Insulin lispro
Insulin aspart
Insulin glulisine)
short-acting (Regular insulin)
long-acting (Insulin glargine
Insulin detemir
NPH insulin)
ultra-long-acting (Insulin degludec^†)
inhalable Exubera^‡
Afrezza

Other

Aldose reductase inhibitors	Epalrestat Fidarestat^§ Ranirestat^† Tolrestat^‡ Zenarestat^§

Alpha-glucosidase inhibitors	Acarbose Miglitol Voglibose

Amylin analog	Pramlintide

Sodium glucose transporter (SGLT2) inhibitors	Canagliflozin Dapagliflozin Empagliflozin Remogliflozin^§ Sergliflozin^§ Tofogliflozin^†

Other	Benfluorex^‡ Bromocriptine

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Friday, February 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.